Company
Headquarters: Haikou, China
Employees: 2,008
CN¥6.92 Billion
CNY as of Jan. 1, 2025
US$948.4 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's respiratory and digestive systems in China. Its primary products include 4 grams of pediatric lung heat cough granules and capsules. The company was founded in 2005 and is based in Haikou, China.
Hainan Huluwa Pharmaceutical Group Co. Ltd has the following listings and related stock indices.
Stock: SSE: 605199 wb_incandescent